Evidence map›Paper›PMID 41631295›Full record

ReviewExpert review of clinical immunology2026

Myocardial involvement in inflammatory myopathies: from subclinical disease to life-threatening myocarditis.

Albert Gil-Vila, Ernesto Trallero-Araguás, Clara Edo-Fernandez, Iago Pinal-Fernandez, Aitor Uribarri, Hug Cuellar-Calabria, Albert Selva-O'Callaghan

Abstract readReview
In one paragraph

Review in Expert review of clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Albert Gil-VilaSystemic Autoimmune Diseases Unit., Internal Medicine Department, Vall d'Hebron General Hospital, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ernesto Trallero-AraguásRheumatology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Clara Edo-FernandezSystemic Autoimmune Diseases Unit., Internal Medicine Department, Vall d'Hebron General Hospital, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.
Iago Pinal-FernandezMuscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Aitor UribarriCardiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Hug Cuellar-CalabriaCardiovascular Imaging Area, Diagnostic Imaging Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Albert Selva-O'CallaghanSystemic Autoimmune Diseases Unit., Internal Medicine Department, Vall d'Hebron General Hospital, Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID 0000-0003-2823-9761

Funding

European Regional Development FundEuropean UnionInstituto de Salud Carlos III PI22/00708Intramural NIH HHS Z99 AR999999
6 · The paper itself

Abstract

introductionInflammatory myopathies (IM) are a heterogeneous group of systemic disorders characterized by chronic muscle inflammation. Cardiac involvement has historically been underrecognized, partially because of its subclinical presentation, and is associated with a poor prognosis, underscoring the urgent need for effective diagnostic strategies and therapeutic approaches. Cardiac magnetic resonance and its new mapping techniques appear as one of the most valuable instruments to detect myocardial involvement, thereby limiting the need for an endomyocardial biopsy when the underlying cause of cardiac dysfunction is unclear or when noninvasive imaging is inconclusive. Evidence-based data remains lacking regarding treatment strategies, and nowadays, immunosuppressive therapy constitutes the cornerstone of treatment. AREAS COVERED: In this review, we provide a summary of the current literature on myocarditis in the context of IM, with a focus on clinical manifestations, underlying pathophysiological mechanisms, diagnostic methods, and therapeutic strategies. EXPERT OPINION: We are currently in a privileged moment regarding IM, as there has never been a time with so many ongoing clinical trials. With growing awareness of cardiac involvement in IM, now is the time to focus research efforts on cardiac involvement in IM to address this underrecognized manifestation that carries significant morbidity and prognostic implications in patients with IM.

Indexed as

MyocarditisMyocardiumMyositisAnimalsHumansImmunosuppressive AgentsMagnetic Resonance ImagingPrognosisImmunosuppressive Agentsautoimmunitycardiac involvementimmune checkpoint inhibitorsinflammatory myopathiesmyocarditisMyositis

Identifiers

PMID41631295
PMCPMC13173391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.